GUIDELINES FOR ABSTRACT SUBMISSION
PLEASE READ CAREFULLY
Abstracts that do not meet these criteria will not be accepted.
Studies and case reports in all areas of Plastic Surgery will be considered suitable for presentation: history, research, basic science, all different types of reconstructions, congenital malformations, aesthetic surgery, burns, traumas, flaps, microsurgery, etc. To achieve a balanced final program, papers are divided into categories, and abstracts should be submitted accordingly:
The purpose of the investigation should be clearly stated and results must be supplied
- Clinical (General, Cleft/Cranio, Hand/Nerve, Microsurgery)
Data of the prospective/retrospective study along with complications must be produced
Emphasis should be given to the description of the procedure, evaluation of the results and complications
Abstracts should be uniformly written giving a title and using the following headings for the body text
- Materials (not for case reports) and Methods
Names, addresses, institutions must not appear in the text, penalty the exclusion.
Text must be single-spaced, and not exceed 300 words. EURAPS recommends the use of the International System of Units (SI) as the official measurement system to present data.
Abstracts must be submitted in English, correctly spelled and carefully checked. If accepted for presentation, the original text of the submitted abstract will be printed without any changes or corrections in the final abstract book.
Toll-like receptor 4 and estrogen receptors expression in human breast implant
Capsular contracture often complicates breast augmentation and reconstruction. Fibroblasts are responsible for the production of extracellular matrix (ECM) and proinflammatory signals. They can differentiate into myofibroblasts, which are involved in the pathogenesis of capsular contracture. Toll-like receptor 4 (TLR4) has been demonstrated to play a role as a biosensor of tissue damage and sterile inflammation; it is overexpressed in keloids and hypertrophic scars. TLR4 stimulation in fibroblasts induces transcription of genes involved in ECM remodeling and tissue repair; furthermore, it enhances sensitivity to TGF-?1 and promotes transition to myofibroblasts. In TLR4-/- mice implanted with silicone shells, the inflammatory infiltrate, capsular thickness, VEGF and TGF-?1 were reduced. Seventeen-?-estradiol promotes myofibroblasts contraction and differentiation by mean of TGF-?; moreover, it increases the expression of TLR4 and the production of pro-inflammatory mediators by macrophages. Estrogen receptor-? (ER-?) stimulation induces conversion of fibroblast into myofibroblast, while estrogen receptor-? (ER-?) activation promotes ECM production and increases wound tensile strength. The aim of the study was to investigate the expression of TLR4 in breast implant capsules and its relationship with estrogen receptors, collagen types and angiogenesis.
Material and Methods:
The study enrolled 30 women who underwent expander removal following breast reconstruction. Specimens were stained with Hematoxylin/Eosin, Masson trichrome, immunohistochemistry and immunofluorescence for TLR4, alpha-Smooth Muscle Actin (?-SMA), ER-? and ER-?, Collagen types I and III, CD31.
TLR4 was expressed by fibroblasts and myofibroblasts of capsular tissue. Its expression positively correlated with ER-? expression (p=0.012). CD31 score and inflammatory infiltrate negatively correlated with the time from implantation (p=0.06 and p=0.022, respectively).
This study demonstrates the expression of TLR4 in fibroblasts of capsular tissue and its correlation with ER-? positivity. TLR4 and ER-? activations, as well as their interplay, may be involved in myofibroblasts differentiation and in the pro-fibrotic pathogenic process underlying capsular contracture.
Abstract submission is open to Plastic Surgeons, including young residents in training and fellow researchers.
Non-members of the association must indicate the name of a EURAPS or AAPS Member to sponsor their abstract submission. The sponsoring member must previously read the abstract and agree to its submission. After submission, the member is automatically contacted by the EURAPS Office to confirm their sponsorship to the submitting author.
Authors can submit a maximum of 2 abstracts.
Abstracts must be submitted online via the EURAPS website by 1st December 2017.
EURAPS presentations are of 4 or 8 minutes.
Submitters indicate the preferred presentation time, however it is up to the discretion of the Secretary General and the Scientific Committee to resize the length of the presentation, if necessary.
Case reports will automatically be given a presentation time of 4 minutes.
A 4-minute discussion will follow the given time of each presentation: 4+4 or 8+4.
Speakers must adhere to the given minutes, as the presentation will be stopped as soon as the time is up.
A preliminary program will be issued at the beginning of February 2018. Authors can check the EURAPS website at this time to view the date and time of their presentation.
To avoid misunderstandings, the time appearing on the schedule is the sum of the given speaking-time decided by the Scientific Committee, with the addition of 4 minutes of discussion.
The Scientific Committee, composed of 18 reviewers, will give an anonymous evaluation and review of the abstracts. Only the best in each category, selected according to methodical criteria, are accepted for presentation at the Annual Meeting.
The person whose name appears as ‘first author’ will be presenting the accepted abstract. Onsite substitution of absent first authors by co-authors, or other participants to the meeting, will not be possible.
In case 2 abstracts from the same author are accepted, the first author will present one of them and give the second presentation to one of the co-authors.
No-shows will be excluded from the final program and abstract book, and will not be considered as prerequisite of an application for EURAPS membership.
Without acceptable excuse, not-showing authors will be automatically excluded from paper submission to future EURAPS Meetings.
EURAPS website accepts up to two (n. 2) abstracts per first author, however in case both abstracts pass review and make it to the final program, the author will choose one of the two abstracts. The second abstract will be automatically presented by the next co-author available. Attempts of submission after 2 abstracts will be rejected.
EURAPS has a strict policy against plagiarism, and has implemented software that verifies authenticity and originality of papers. Multiple submissions of the same abstracts with different authors, different titles, in different categories, submission of abstracts with similar texts, are strictly forbidden. Any infraction will be immediately identified and lead to the complete exclusion of the abstract(s) from further evaluation and complete exclusion of the author(s) from future EURAPS Meetings.
In accordance with EURAPS by-laws, authors are requested to be sensitive to, and show respect for, ethnic, cultural, religious, and gender diversity.